Skip to content
Open access · CC-BY via OpenAlex

Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia

Bram van der Gaag, Natasja A. C. Deshayes, John J. P. Brevé, John G. J. M. Bol, Allert J. Jonker, Jeroen J.M. Hoozemans, Jean‐Philippe Courade, Wilma D. J. van de Berg

Acta Neuropathologica · 2024 · ▲ 44 citations

Abstract

Alpha-synuclein (aSyn) pathology is present in approximately 50% of Alzheimer's disease (AD) cases at autopsy and might impact the age-of-onset and disease progression in AD. Here, we aimed to determine whether tau and aSyn profiles differ between AD cases with Lewy bodies (AD-LB), pure AD and Parkinson's disease with dementia (PDD) cases using epitope-, post-translational modification- (PTM) and isoform-specific tau and aSyn antibody panels spanning from the N- to C-terminus. We included the middle temporal gyrus (MTG) and amygdala (AMY) of clinically diagnosed and pathologically confirmed cases and performed dot blotting, western blotting and immunohistochemistry combined with quantitative and morphological analyses. All investigated phospho-tau (pTau) species, except pT181, were upregulated in AD-LB and AD cases compared to PDD and control cases, but no significant differences were observed between AD-LB and AD subjects. In addition, tau antibodies targeting the proline-rich regions and C-terminus showed preferential binding to AD-LB and AD brain homogenates. Antibodies targeting C-terminal aSyn epitopes and pS129 aSyn showed stronger binding to AD-LB and PDD cases compared to AD and control cases. Two pTau species (pS198 and pS396) were specifically detected in the soluble protein fractions of AD-LB and AD subjects, indicative of early involvement of these PTMs in the multimerization process of tau. Other phospho-variants for both tau (pT212/S214, pT231 and pS422) and aSyn (pS129) were only detected in the insoluble protein fraction of AD-LB/AD and AD-LB/PDD cases, respectively. aSyn load was higher in the AMY of AD-LB cases compared to PDD cases, suggesting aggravated aSyn pathology under the presence of AD pathology, while tau load was similar between AD-LB and AD cases. Co-localization of pTau and aSyn could be observed within astrocytes of AD-LB cases within the MTG. These findings highlight a unique pathological signature for AD-LB cases compared to pure AD and PDD cases.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1007/s00401-023-02657-y
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Gaag, B.V.D., Deshayes, N.A.C., Brevé, J.J.P., Bol, J.G.J.M., Jonker, A.J., Hoozemans, J.J., Courade, J., &amp; Berg, W.D.J.V.D. (2024). Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia. <em>Acta Neuropathologica</em>. https://doi.org/10.1007/s00401-023-02657-y
Vancouver
Gaag BVD, Deshayes NAC, Brevé JJP, Bol JGJM, Jonker AJ, Hoozemans JJ, et al. Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia. Acta Neuropathologica. 2024. doi:10.1007/s00401-023-02657-y.
BibTeX
@article{bram2024Distin, title = {Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia}, author = {Bram van der Gaag and Natasja A. C. Deshayes and John J. P. Brevé and John G. J. M. Bol and Allert J. Jonker and Jeroen J.M. Hoozemans and Jean‐Philippe Courade and Wilma D. J. van de Berg}, journal = {Acta Neuropathologica}, year = {2024}, doi = {10.1007/s00401-023-02657-y}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings